<DOC>
	<DOCNO>NCT00152295</DOCNO>
	<brief_summary>The objective study determine long-term safety asoprisnil 10 mg administer postmenopausal woman Premarin® 0.625 mg</brief_summary>
	<brief_title>A Long-Term Study Evaluate Safety Asoprisnil Estrogen Administration Postmenopausal Women</brief_title>
	<detailed_description>The objective study determine long-term safety asoprisnil 10 mg ( 2-5mg tablet ) take Premarin® 0.625 mg , postmenopausal woman , 6 month initial 12 week Study M00-198 . Pharmacodynamic effect assess include uterine bleeding pattern , endometrial biopsy result , endometrial thickness . Safety assessment include clinical laboratory result , physical examination vital sign , pelvic breast examination , ultrasound result , adverse event .</detailed_description>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<criteria>Successful completion study M00198 Continued good general health Negative urine pregnancy test History know suspect cancer basal cell carcinoma last 5 year History reproductive endocrine disorder Submucous symptomatic fibroid would confound efficacy Ovarian mass Ongoing treatment exclude medication Stenosis cervix Any abnormal lab result studydoctor considers significant .</criteria>
	<gender>Female</gender>
	<minimum_age>48 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Postmenopausal</keyword>
	<keyword>Amenorrhea</keyword>
	<keyword>Hormone replacement therapy</keyword>
	<keyword>HRT</keyword>
	<keyword>asoprisnil</keyword>
	<keyword>Estrogen Replacement Therapy , postmenopause</keyword>
</DOC>